본문 바로가기


(* You can scroll left and right)

이 표는 수집하는 개인정보 항목 및 수집방법, 개인정보의 수집목적 및 이용목적, 개인정보의 공유 및 제공, 수집한 개인정보 처리 위탁, 수집한 개인정보의 보유 및 이용기간, 개인정보 파기절차 및 방법, 이용자 및 법정대리인의 권리와 그 행사방법, 쿠키의 운영과 활용(자동수집장치 설치, 운영, 거부에 관한 사항), 개인정보 보호를 위한 이용자의 주의사항, 개인정보 관리 책임자, 부칙 구성되어 있습니다.
Therapeutic Area Project Code Target Indication Development Stage Note
Lead NME Clinical NDA Product
Liver Disease ID119031166 NASH
FXR agonist
Liver Disease ID119050134 Hepatic cirrhosis
ATX inhibitor
Metabolic Disease IDG16177 Type-2 Diabetes
GPR40 agonist
Metabolic Disease ID110521156 Type-2 Diabetes
GLP-1R agonist
CNS ID119040338 Parkinson's Disease
A2A antagonist
Collaboration (with ILeadBMS)
Ophthalmology IDB0062 Wet AMD
VEGFA/NRP1 dual inhibitor
Ophthalmology ID110410395 Dry Eye Disease
CFTR activator/PDE4 inhibitor
Gastrointestinal Disease ID120040002 GERD
Oncology venadaparib Breast Cancer
PARP inhibitor
Developement by subsidiary(idience)
Oncology ID119160021 Breast Cancer
4th Antiandrogen
Developement by subsidiary(idience)

Liver Disease

• A potent non-steroidal FXR agonist to treat NASH:
 - Mechanism of action that inhibits the synthesis of bile acid
 - Strong activity and selectivity demonstrated in nonclinical studies
 - Significantly reduced NAFLD Activity score and fibrosis in animal models of NASH
 - Regulated direct FXR target genes in a dose-dependent manner in vivo
 - Not importantly altered plasma level of ALT/AST and LDL-C at the effective dose
• Phase 1 has started in US in October to evaluate safety and pharmacokinetics
 - Phase I Single Assending dose study in Progress

NASH : NonAlcoholic SteatoHepatitis, NAFLD : NonAlcoholic Fatty Liver Disease,
FXR : Farnesoid X Receptor, ALT : Alanine aminotransferase,
AST : Aspartate aminotransferase, LDL-C : Low-Density Lipoprotein Cholesterol


Liver Disease

• A potent ATX inhibitors for Liver cirrhosis treatment
• ID119050134 inhibits the production of LPA by ATX and inhibits the differentiation of Hepatic Stellate Cell (HSC) into Myofibroblast with strong fibrogenic activity
• Phase 1 IND submission is planned in 2024

ATX: Autotaxin LPA: Lysophosphatidic acid HSC: Hepatic stellate cell



• Migraine therapy with an innovative mechanism of action with no restrictions on use in cardiovascular disease patients
 - The first and only Ditan drug approved by the FDA with a different mechanism from triptans (serotonin 1B receptor agonists) and NSAIDs, which have been used as migraine treatments.
 - Overcoming the limitations of existing triptans (limited use in cardiovascular patients) by exhibiting 470-fold or more affinity for serotonin 1F receptors compared to serotonin 1B and 1D receptors associated with vasoconstriction
• NDA approval by MFDS on May 2022

NSAIDs : Non-steroidal anti-inflammatory drugs



• A Novel Non-dopaminergic treatment for Parkinson’s disease
  - First-In-Class Adenosine A1/A2A Dual Receptor Antagonist
  - Exceptional drug absorption and excellent BBB (Blood-Brain Barrier) permeability
  - (ID119040338) Demonstrated superior efficacy in long-term duration and in behavioral improvement(or motor and non-motor symptoms) compared to other drugs in MPTP-monkey models.
  - Expected to improve non-motor symptoms in Parkinson’s disease through Adenosine A1/A2a Dual Receptor Antagonism
• IND Application expected in 2024


Metabolic Disease

• A GPR40 agonist to treat type 2 diabetes mellitus
 - High oral absolute bioavailability in pre-clinical species
 - A defined MoA, activating β-arrestin2 recruitment as well as Gq-dependent pathway
 - Glucose-dependent insulin secretion & free of hypoglycemic risk
 - Superior to fasiglifam in glucose reduction in normal and diabetic rat studies
 - Potentially no risk of DILI (drug-induced liver injury)
Phase 1 has started in Germany in July 2021 to evaluate safety and pharmacokinetics (NCT04982705) • Phase 1 (SAD, MAD) completed in August 2022
• Phase 1 patient dosing protocol submitted by BfArM in Oct 2022
• Phase I clinical trials for patients was administered in January 2023.
• Completed recruitment of subjects for Phase 1 clinical trial in patients in May 2023


Metabolic Disease

•A small-molecule glucagon-like peptide (GLP)-1 receptor agonist to treat type 2 diabetes
 - Being developed as an oral drug
 - A defined MoA, increasing intra-cellular cAMP levels through the activation of Gα subunit pathway
 - No risk for hypoglycemic shock by glucose-dependent insulin secretion
 - Overcame the disadvantages of existing injection drugs (improved safety profile and
    patient adherence)
 - Potential of expansion to various indications including obesity and NASH
• Completion of nonclinical trials and IND writing (CTD/IB) in Q2 2023
• IND filing in Q2 2023

GLP-1 : Glucagon-like peptide-1, NASH : NonAlcoholic SteatoHepatitis


Gastrointestinal Disease

A novel Potassium-Competitive Acid Blocker (P-CAB) to treat gastric acid related diseases:
 - Strong inhibition of proton pump (H+/K+ ATPase)
 - Long retention time in stomach for effective proton pump inhibition
 - Inhibition of basal gastric acid secretion and fast-onset of efficacy in vivo

MFDS IND approval in Nov 2022
Phase 1 Single Ascending Dose Completed. Multiple Ascending Dose in Progress



• A dual-targeting antibody fragment drug for wet AMD
 - A dual target antibody fragment in which a tissue penetrating peptide targeting NRP1 is linked to the anti-VEGFA antibody fragment
 - Stronger efficacy by inhibition of multiple pathological growth factors in ocular angiogenic diseases(VEGF-A, -B, -C, PlGF2, PDGFBB)
 -Delay and suppression of subretinal fibrosis formation through macrophage regulation
 - Expected extended dosing interval based on improved ocular PK profile(Once every 2 or 3 months)
 - Possibility on less invasive treatment through tissue-penetrating peptides
• Possibility of absence of ocular/systemic side effects through toxicological benefit​
• Manufacturing strain established with Global CDMO


• First-in-class small molecule CFTR activator to treat dry eye disease
  - A novel mode of action in which DED symptoms are improved by restoration of tear film homeostasis through tear secretion and anti-inflammatory action.
 - targets to improve both signs and symptoms with favorable tolerability profile and simplified dosing
• IND submission expected in H1 2022

CFTR : Cystic Fibrosis Transmembrane Conductance Regulator



• A nitric oxide-donating PDE5 inhibitor for Glaucoma
 - Metabolized in the body to release nitric oxide and at the same time inhibits PDE5/6 to
     increase PKG (protein kinase G) activity
 - Activates PKG by increasing the amount of cGMP by inhibiting the degradation of cGMP
 - Activated PKG relaxes smooth muscle and increases blood flow

cGMP : Cyclic Guanosine MonoPhosphate


Respiratory Disease

• A nitric oxide-donating PDE5 inhibitor for ARDS, PAH
 - Highly selective and potent in vitro activity
 - Efficacy shown in an acute lung injury mouse model
• in vivo efficacy study, formulation, PK analysis are on-going
• IND submission expected in 1Q 2023

ARDS : Acute Respiratory Distress Syndrome, PDE5 : PhosphoDiEsterase 5


* FXR agonist : Investigational New Drug Application(IND) approval in July 2022 in USA

* P-CAB : Investigational New Drug Application(IND) approval in November 2022 in Korea

* YUHS : Yunsei University Health System

최상단으로 바로가기